Abstract
Background: Psoriasis therapeutic goals extend beyond Psoriasis Area and Severity Index (PASI) improvement to reducing psoriasis involvement in special areas and improving patients’ overall well-being. We present the effect of apremilast on the Dermatology Life Quality Index (DLQI), pruritus, and nail, scalp, and palmoplantar involvement in PASI-75 nonresponders.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have